公开(公告)号：US20190154672A1

公开(公告)日：2019-05-23

申请号：US16313316

申请日：2017-06-30

Applicant: Randox Laboratories Ltd. ,  Randox Teoranta

Inventor： Ivan McConnell ,  Peter Fitzgerald ,  John Lamont ,  Ciaran Richardson

IPC: G01N33/543 ,  G01N33/92 ,  C07K16/18

Abstract: The present invention relates to a multiplexing system comprising a support substrate having immobilised thereto one or more of the following proteins, fragments thereof or a binding molecule, wherein the binding molecule binds specifically to one of the following proteins: E-FABP, B-FABP, IL-FABP, I-FABP, M-FABP, A-FABP, H-FABP, L-FABP or T-FABP. Another aspect is directed to a method for characterising the pattern of FABP antigens existing within a biological sample to reveal information useful in the diagnosis or disease or injury.

公开(公告)号：US10175258B2

公开(公告)日：2019-01-08

申请号：US14536163

申请日：2014-11-07

Applicant: RANDOX LABORATORIES LIMITED

Inventor： Stephen Peter Fitzgerald ,  Paul John Innocenzi ,  Ivan Robert McConnell ,  Philip Andrew Lowry ,  Elouard Benchikh

IPC: G01N33/94 ,  C07K16/44 ,  C07K17/14

Abstract: The invention describes methods and kits for detecting and determining current and future synthetic cannabinoids from the JWH and CP families. Unique antibodies derived from novel immunogens enable said methods and kits.

公开(公告)号：US09863966B2

公开(公告)日：2018-01-09

申请号：US14048325

申请日：2013-10-08

Applicant: Randox Laboratories Limited

Inventor： Ivan McConnell ,  Elouard Benchikh ,  Philip Lowry ,  Peter Fitzgerald

IPC: G01N33/94 ,  C07K16/44 ,  A61K47/48

CPC classification number: G01N33/94 ,  A61K47/643 ,  A61K47/646 ,  C07K16/44 ,  C07K2317/33

Abstract: The invention provides novel haptens and immunogens for the preparation of novel monoclonal antibodies, which detect the synthetic opioid meperidine and its active metabolite normeperidine. These antibodies enable methods and kits, which are useful in an immunoassay for therapeutic drug monitoring (TDM) and in extending the window of detection for cases of abuse and drug-facilitated sexual assault (DFSA).

公开(公告)号：US09784752B2

公开(公告)日：2017-10-10

申请号：US13861093

申请日：2013-04-11

Applicant: Randox Laboratories, Limited

Inventor： Elouard Benchikh ,  Ivan McConnell ,  Philip Lowry ,  Peter Fitzgerald

IPC: G01N33/94 ,  C07C217/64

CPC classification number: G01N33/9466 ,  C07C217/64

Abstract: The invention describes antibodies that bind venlafaxine and O-desmethylvenlafaxine. The antibodies are derived from novel haptens and immunogens and are used in methods and kits to detect and quantify venlafaxine and O-desmethylvenlafaxine. The invention also describes novel detecting agents which can be used in the methods and kits of the invention.

公开(公告)号：US09720005B2

公开(公告)日：2017-08-01

申请号：US14723724

申请日：2015-05-28

Applicant: Randox Laboratories Limited

Inventor： Ivan Robert McConnell ,  Elouard Benchikh ,  Peter Fitzgerald ,  Andrew Philip Lowry

IPC: G01N33/94 ,  C07K16/44

CPC classification number: G01N33/94 ,  C07K16/44 ,  C07K2317/30 ,  C07K2317/33 ,  G01N33/946 ,  G01N2430/00

Abstract: An immunoassay method for detecting and determining ‘NBOMe’ family designer drugs is described. Also described are components for use in implementing the method, namely, antibodies, detection agents, solid state devices and kits as well as immunogens used to raise the antibodies.

公开(公告)号：US20170184611A1

公开(公告)日：2017-06-29

申请号：US15457297

申请日：2017-03-13

Applicant: Randox Laboratories Ltd.

Inventor： John Lamont ,  Ivan Mc Connell ,  Peter Fitzgerald

IPC: G01N33/68

CPC classification number: G01N33/6893 ,  C12Q1/6883 ,  C12Q2600/158 ,  G01N33/6842 ,  G01N2333/4737 ,  G01N2333/5412 ,  G01N2333/70503 ,  G01N2333/70525 ,  G01N2333/70542 ,  G01N2333/70564 ,  G01N2333/7151 ,  G01N2800/2871 ,  G01N2800/32 ,  G01N2800/60

Abstract: The present invention provides biomarker-based methods for diagnosing stroke in a patient suspected of having suffered a stroke, and also for discriminating between ischemic stroke and transient ischemic attack. Substrates comprising probes for specific combinations of biomarkers useful in the methods of the invention are also described.

公开(公告)号：US09587035B2

公开(公告)日：2017-03-07

申请号：US13932087

申请日：2013-07-01

Applicant: Randox Laboratories Limited

Inventor： Elouard Benchikh ,  Ivan McConnell ,  Philip Lowry ,  Peter Fitzgerald

IPC: C07K16/44 ,  C07D295/096

CPC classification number: C07K16/44 ,  C07D295/096 ,  C07K2317/33 ,  C07K2317/76 ,  C07K2317/90

Abstract: The invention relates to the detection and quantification of 1-benzylpiperazine and its metabolites. The invention is underpinned by novel polyclonal antibodies with unique binding properties which enable immunoassay methods and kits for various applications.

Abstract translation: 本发明涉及1-苄基哌嗪及其代谢物的检测和定量。 本发明由具有独特结合特性的新型多克隆抗体支持，其能够进行各种应用的免疫测定方法和试剂盒。

公开(公告)号：US09447469B2

公开(公告)日：2016-09-20

申请号：US14323775

申请日：2014-07-03

Applicant: RANDOX LABORATORIES LTD.

Inventor： John V. Lamont

IPC: C12Q1/68 ,  C12P19/34 ,  A61K31/404 ,  A61K31/4439 ,  A61K31/517

CPC classification number: C12Q1/6883 ,  A61K31/404 ,  A61K31/4439 ,  A61K31/517 ,  C12Q2600/106 ,  C12Q2600/156

Abstract: The present disclosure provides a method for identifying whether a subject is more or less likely to be responsive to VEGF-based therapy, comprising screening a nucleic acid sample obtained from the subject to provide output information which identifies the presence or absence of an allelic variant, wherein the presence or absence of an allelic variant indicates whether the subject is more or less likely to be responsive to VEGF-based therapy.

Abstract translation: 本公开提供了用于鉴定受试者是或多或少可能对基于VEGF的治疗有反应的方法，其包括筛选从受试者获得的核酸样品以提供识别等位变体的存在或不存在的输出信息， 其中等位基因变体的存在或不存在表明受试者是或多或少可能对基于VEGF的治疗有反应。

公开(公告)号：US20160161508A1

公开(公告)日：2016-06-09

申请号：US15043238

申请日：2016-02-12

Applicant: RANDOX LABORATORIES, LTD.

Inventor： Maria ZELLNER ,  Rudolf OEHLER

IPC: G01N33/68 ,  C12Q1/68

CPC classification number: G01N33/6896 ,  C07K14/4711 ,  C12Q1/6883 ,  C12Q2600/158 ,  G01N2333/90638 ,  G01N2800/2814 ,  G01N2800/2821 ,  G01N2800/2835

Abstract: A method for the diagnosis of Alzheimer's Disease (AD) or Parkinson's Disease (PD), including measuring the level of expression of one or more AD markers (Table 1) or PD markers (Table 2) in a sample of platelets isolated from a person suspected of having AD or PD, and determining whether the levels of expression are altered compared to a control.

Abstract translation: 一种用于诊断阿尔茨海默病（AD）或帕金森病（PD）的方法，包括测量从人分离的血小板样品中的一种或多种AD标志物（表1）或PD标志物（表2）的表达水平 怀疑患有AD或PD，并确定与对照相比，表达水平是否改变。

公开(公告)号：US20140147859A1

公开(公告)日：2014-05-29

申请号：US13861093

申请日：2013-04-11

Applicant: Randox Laboratories, Limited

Inventor： Elouard Benchikh ,  Ivan McConnell ,  Philip Lowry ,  Peter Fitzgerald

IPC: G01N33/94 ,  C07C217/64

CPC classification number: G01N33/9466 ,  C07C217/64

Abstract: The invention describes antibodies that bind venlafaxine and O-desmethylvenlafaxine. The antibodies are derived from novel haptens and immunogens and are used in methods and kits to detect and quantify venlafaxine and O-desmethylvenlafaxine. The invention also describes novel detecting agents which can be used in the methods and kits of the invention.

Abstract translation: 本发明描述了结合文拉法辛和O-去甲基文拉法辛的抗体。 抗体衍生自新型半抗原和免疫原，并用于方法和试剂盒中以检测和定量文拉法辛和O-去甲基文拉法辛。 本发明还描述了可用于本发明的方法和试剂盒中的新型检测剂。